ReNerve study shows major patient outcome benefits of NervAlign nerve cuff

Small Caps
03-28

Advanced nerve repair and regeneration solutions specialist ReNerve (ASX: RNV) has identified significant benefits for patient outcomes when using its NervAlign Nerve Cuff technology.

A recent study found that patients undergoing peripheral nerve surgery with the NervAlign Nerve Cuff experienced a major decrease in post-surgery pain measures compared to surgery in which the product was not used.

The investigation also found that average post-operative pain scores decreased from 7.1 to 0.4 with the Nerve Cuff, compared to a reduction from 7.1 to 3.3 without it.

Regenerating nerves

ReNerv developed the NervAlign Nerve Cuff to help protect repaired and regenerating nerves during the healing process after peripheral nerve injuries or surgery.

NervAlign is naturally absorbed into the body within six months, leaving only regenerated and repaired tissue.

The study – presented this week at the American College of Foot and Ankle Surgeons annual conference in Arizona – also found that patients treated with the Nerve Cuff reported higher satisfaction with their surgery compared to those who did not receive the Nerve Cuff.

93% of the former said they would elect to have surgery again, as opposed to 70% of the latter.

Significant results

ReNerve chief executive officer Dr Julian Chick said that the medical properties of the NervAlign Nerve Cuff make it suitable for use in a wide range of surgical procedures.

“These are very significant results for the development of ReNerve’s products, as they highlight the utility of the NervAlign Nerve Cuff in reducing patients’ pain following peripheral nerve surgery,” Dr Chick said.

“The results clearly demonstrate the patient benefits that follow from the proper repair and regeneration of a nerve that is returned to normal function post-surgery.”

“The NervAlign Nerve Cuff facilitates the patient’s repair process and protects it during the initial post-operative recovery and regeneration period.”

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10